Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London
· Delayed Price · Currency is GBP · Price in USD 262.11
+2.19 (0.84%)
At close: May 12, 2025
Alnylam Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,348 | 2,248 | 1,828 | 1,037 | 844.29 | 492.85 | Upgrade
|
| Revenue Growth (YoY) | 17.21% | 22.97% | 76.23% | 22.88% | 71.31% | 124.28% | Upgrade
|
| Cost of Revenue | 328.44 | 323.37 | 310.41 | 168.82 | 140.14 | 78.05 | Upgrade
|
| Gross Profit | 2,020 | 1,925 | 1,518 | 868.6 | 704.14 | 414.8 | Upgrade
|
| Selling, General & Admin | 1,005 | 975.53 | 795.65 | 770.66 | 620.64 | 588.42 | Upgrade
|
| Research & Development | 1,130 | 1,126 | 1,004 | 883.02 | 792.16 | 654.82 | Upgrade
|
| Operating Expenses | 2,135 | 2,102 | 1,800 | 1,654 | 1,413 | 1,243 | Upgrade
|
| Operating Income | -115.37 | -176.89 | -282.18 | -785.07 | -708.65 | -828.44 | Upgrade
|
| Interest Expense | -145.25 | -141.86 | -121.22 | -155.97 | -143.02 | -84.5 | Upgrade
|
| Interest & Investment Income | 121.02 | 121.99 | 95.56 | 24.81 | 1.58 | 11.81 | Upgrade
|
| Other Non Operating Income (Expenses) | -211.72 | -177.6 | -108.74 | -100.86 | -57.75 | -8.52 | Upgrade
|
| EBT Excluding Unusual Items | -351.33 | -374.35 | -416.57 | -1,017 | -907.84 | -909.64 | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.06 | -3.02 | -16.94 | -33.31 | 55.7 | 54.04 | Upgrade
|
| Other Unusual Items | - | - | - | -76.59 | - | - | Upgrade
|
| Pretax Income | -355.38 | -377.38 | -433.52 | -1,127 | -852.14 | -855.6 | Upgrade
|
| Income Tax Expense | -85.68 | -99.22 | 6.73 | 4.16 | 0.68 | 2.68 | Upgrade
|
| Net Income | -269.7 | -278.16 | -440.24 | -1,131 | -852.82 | -858.28 | Upgrade
|
| Net Income to Common | -269.7 | -278.16 | -440.24 | -1,131 | -852.82 | -858.28 | Upgrade
|
| Shares Outstanding (Basic) | 129 | 128 | 125 | 122 | 118 | 115 | Upgrade
|
| Shares Outstanding (Diluted) | 129 | 128 | 125 | 122 | 118 | 115 | Upgrade
|
| Shares Change (YoY) | 2.49% | 2.20% | 2.64% | 2.73% | 3.01% | 5.24% | Upgrade
|
| EPS (Basic) | -2.10 | -2.18 | -3.52 | -9.30 | -7.20 | -7.46 | Upgrade
|
| EPS (Diluted) | -2.10 | -2.18 | -3.52 | -9.30 | -7.20 | -7.46 | Upgrade
|
| Free Cash Flow | -75.39 | -42.59 | 41.95 | -613.33 | -718.07 | -685.32 | Upgrade
|
| Free Cash Flow Per Share | -0.59 | -0.33 | 0.34 | -5.04 | -6.06 | -5.96 | Upgrade
|
| Gross Margin | 86.01% | 85.62% | 83.02% | 83.73% | 83.40% | 84.16% | Upgrade
|
| Operating Margin | -4.91% | -7.87% | -15.43% | -75.68% | -83.94% | -168.09% | Upgrade
|
| Profit Margin | -11.49% | -12.37% | -24.08% | -109.04% | -101.01% | -174.14% | Upgrade
|
| Free Cash Flow Margin | -3.21% | -1.89% | 2.29% | -59.12% | -85.05% | -139.05% | Upgrade
|
| EBITDA | -57.82 | -120.22 | -228.12 | -740.6 | -661.09 | -793.67 | Upgrade
|
| EBITDA Margin | -2.46% | -5.35% | -12.48% | -71.39% | -78.30% | -161.03% | Upgrade
|
| D&A For EBITDA | 57.56 | 56.67 | 54.05 | 44.47 | 47.57 | 34.77 | Upgrade
|
| EBIT | -115.37 | -176.89 | -282.18 | -785.07 | -708.65 | -828.44 | Upgrade
|
| EBIT Margin | -4.91% | -7.87% | -15.43% | -75.67% | -83.94% | -168.09% | Upgrade
|
| Revenue as Reported | 2,348 | 2,248 | 1,828 | 1,037 | 844.29 | 492.85 | Upgrade
|
| Advertising Expenses | - | 29.7 | 12.4 | 11.7 | - | - | Upgrade
|
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.